Therapeutic efficacy of chemotherapy with VIP for small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 7, Issue 2, 2004, Pages 151-153

  Wu, Changgui ^a   Qi, Haowen ^a   Dai, Yanli ^a   Li, Shujun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Etoposide; Ifosfamide; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 1942471014     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Pasini F, Durante E, De Manzoni D, et al. High-dose chemotherapy in small-cell lung cancer. Anticancer Res, 2002, 22 (6B): 3465-3472.
2. lhde DC, Mulshine JL, Kramar BS, et al. Randomized trial of high vs standard dose etoposide (VP16) and cisplatin in extensive stage small cell lung cancer (abstract). Proc Am Soc Clin Oncol, 1991, 10 (1): 240.
3. Simon GR, Wagner H, American College of Chest Physicians. Small cell lung cancer. Chest, 2003, 123(1 Suppl): 259S-271S.
4. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999, 17 (2): 658-667.